Active — Not RecruitingNot Applicable

Features of the Clinical Course and Prognosis in Patients With Idiopathic Pulmonary Hypertension When Using Modern Strategies of Specific Therapy

Russia150 participantsStarted 2023-05-30

Plain-language summary

This study will be performed based on a retrospective analysis of the cases of 150-170 patients with IPAH observed at the Research Institute of Clinical Cardiology over the past 10 years, for a comparative assessment of the survival of groups of patients with IPAH diagnosed in the period 2004-2013 and 2014-2023. The demographic, clinical, functional, hemodynamic characteristics of patients, comorbidity, blood biomarker levels, received PAH-specific and symptomatic therapy will be assessed in order to determine the clinical characteristics of patients with IPAH. The prospective part of study will include 50 patients with IPAH.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * age over 18 years; * verified diagnosis of IPAH Exclusion Criteria: * age under 18 years; * Other etiology op PAH, * ischemic heart disease confirmed by MSCT of the coronary arteries or coronary angiography; * diseases of the musculoskeletal system that prevent 6MWT * severe liver dysfunction (more than 9 points on the Child-Pugh scale, class C) * severe renal dysfunction (CC less than 15 ml/min), need for hemodialysis

What they're measuring

Mortality in 3 years after diagnosed IPAH

Timeframe: 3 years

Trial details

NCT IDNCT06587074

SponsorRussian Cardiology Research and Production Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-08-14

View on ClinicalTrials.gov More Idiopathic Pulmonary Arterial Hypertension trials